Roche's sub-Q MabThera wins European panel nod; NICE says no to 'societal benefit' test on drugs;

@FiercePharma: Merck KGaA CFO jumps ship amid turnaround he helped engineer; shares slide. Story | Follow @FiercePharma

@TracyStaton: Q4 sales up, 2013 down, esp in US: Bristol-Myers Squibb Reports 4th Quarter and Full Year 2013 Results. Release | Follow @TracyStaton

@EricPFierce: Ranbaxy will need new markets as FDA closes window on U.S., analysts predict. Piece | Follow @EricPFierce

@CarlyHFierce: Bristol-Myers impresses with trimmed-down costs, pumped-up sales. Story | Follow @CarlyHFierce

> Roche's ($RHHBY) subcutaneous formulation of the cancer drug MabThera won a key recommendation for European approval in non-Hodgkin lymphoma. Report

> The U.K.'s cost-effectiveness agency rejected the idea of using a "wider societal benefit" test when evaluating new drugs for use by the National Health Service. Report

> The family of an inmate recently executed in Ohio sued Lake Forest, IL-based Hospira ($HSP), saying the company illegally allowed its drugs to be used for an execution; the company says its distributors have promised not to sell the drugs to prisons. Report

> Hungary's Gedeon Richter said it won European marketing approval for repeated use of Esmya to treat symptoms of uterine fibroids. Report (sub. req.)

> India's Cadila Healthcare decided to pull out of Japan as part of a strategic review of its business. Report

Medical Device News

@FierceMedDev: U.K. researchers unveil an artificial pancreas they've been developing for 20 years. News | Follow @FierceMedDev

@MichaelGFierce: St. Jude places its first Nanostim leadless pacemaker in a U.K. patient. Story | Follow @MichaelGFierce

@EmilyWFierce: Johnson & Johnson's Animas launches new combination insulin pump in Canada. Article | Follow @EmilyWFierce

@GalenMoore: Pfizer misses its endpoint for 2 PhIII trials of dacomitinib in non-small cell lung cancer. Release | Follow @GalenMoore

> 23andMe's genome test raises more questions, this time for ancestry results. Item

> Varian, Toshiba announce a $515M medical imaging deal. More

> Edwards nabs EU nod for next-gen Sapien as competition mounts. News

Biotech News

@FierceBiotech: Is Bristol-Myers fading back in its hot race with Merck for PD-1 lead? More | Follow @FierceBiotech

@JohnCFierce: Scoff warning: This buyout story relates to experimental dendritic cell cancer vaccine tech. Story | Follow @JohnCFierce

@DamianFierce: ICYMI: Big-time pharma contractor Catalent lines up for an IPO worth $100M--or much more. Article | Follow @DamianFierce

@EmilyMFierce: Study: mutations in Russian #TB strain make it drug-resistant. Story via Wired UK | Follow @EmilyMFierce

> Tsunami of biotech IPOs will test investors' appetite for R&D. Article

> A top Pfizer drug flops in two PhIII lung cancer studies. Piece

CRO News

> Report: Indian clinical trials fell 93% last year. Story

> CRO Genae reaches into Germany for device trials. News

> ResearchDx pushes into the Middle East for diagnostics development. Article

> Catalent lines up for an IPO worth $100M--or much more. More

> Covance adding 500 jobs in U.K. nutrition expansion. Piece

> Datatrak, Clinverse team up for clinical trial tech. Item

Biotech IT News

> The clinical trial technology sector could top $5B by 2018, report says. Story

> Sony teams with Illumina to crack the Japanese genome market. More

> Report: Pharma is missing a Big Data opportunity by ignoring social media. News

> The NCI is offering $20M to pilot projects that move cancer genomics into the cloud. Piece

> U.K. to digitize patient health records and sell access to biopharma researchers. Article

> Novo Nordisk taps Trialbee for online recruitment of trial patients. Item

And Finally... A gap in life expectancy between city and country dwellers is widening. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.